Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lymphoma, non-Hodgkin lymphoma, child
Stage/Subtype:  stage I childhood anaplastic large cell lymphoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-16 of 16 for your search:
Start Over
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Phase: Phase III
Type: Treatment
Age: 65 and under
Trial IDs: CB-AB006, NCI-2013-00758, 2012-0166, NCT01854567
Autologous or Donor Cytotoxic T-Lymphocytes in Treating Patients with Epstein-Barr Virus-Positive Hematologic Malignancy
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: ALCI, NCI-2012-00653, 9936-ALCI, H-9936, NCT00070226, NCT00671164, NCT00062868
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NA_00039823 / CIR00009182, NCT01203722
Donor Stem Cell Transplant with Mismatched Donors and High-Dose Post-Transplant Cyclophosphamide in Treating Patients with Hematologic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 65
Trial IDs: 2009-0266, NCI-2011-03144, NCT01010217
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Immune Therapy in Treating Patients with Epstein-Barr Virus Lymphoproliferative Disorders or Epstein-Barr Virus-Associated Malignancies
Phase: Phase II
Type: Diagnostic, Treatment
Age: any age
Trial IDs: 11-130, NCI-2012-00594, NCT01498484
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
Phase: Phase II
Type: Treatment
Age: 15 to 55
Trial IDs: FT1050-03, NCI-2013-00116, NCT01627314
Safety Study of Cord Blood Units for Stem Cell Transplants
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093
Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes in Treating Patients With Newly Diagnosed or Recurrent Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: CAR CD30, NCI-2012-00640, H-26617, NCT01192464
Donor Cytotoxic T-Lymphocytes in Treating Patients With Relapsed Epstein-Barr Virus-Associated Diseases
Phase: Phase I
Type: Treatment
Age: Any age
Trial IDs: MALTED, NCI-2012-01079, H-28361, NCT01447056
Modified T-Cells in Treating Patients With Epstein-Barr Virus Positive Lymphoma.
Phase: Phase I
Type: Treatment
Age: Not specified
Trial IDs: H-29617, NCI-2013-01016, GRALE, NCT01555892
Unrelated Donor Stem Cell Transplant in Treating Patients With Malignant and Non-Malignant Disorders
Phase: No phase specified
Type: Treatment
Age: 0 to 55
Trial IDs: AAAB3095, NCI-2011-00361, NCT01050439
Proton Beam Radiation Therapy in Treating Patients with Hodgkin and Non-Hodgkin Lymphoma Involving the Mediastinum
Phase: No phase specified
Type: Treatment
Age: 6 and over
Trial IDs: 12-346, NCI-2013-00625, NCT01751412
CD34+ Stem Cell Selection in Treating Younger Patients with Malignant Disease Undergoing Donor Stem Cell Transplant
Phase: No phase specified
Type: Treatment
Age: Under 22
Trial IDs: AAAK8060, NCI-2014-00137, NCT02061800
Start Over